Cancer risk in adherent users of polyurethane foam-containing CPAP devices for sleep apnoea

Eur Respir J. 2022 Jul 13;60(1):2200551. doi: 10.1183/13993003.00551-2022. Print 2022 Jul.

Abstract

Sustained and adherent CPAP therapy of obstructive sleep apnoea using Philips Respironics devices containing polyester-based polyurethane foam, was not associated with an increased risk of cancer after a median follow-up time of 7.2 years https://bit.ly/3vBpUQE

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Continuous Positive Airway Pressure
  • Humans
  • Neoplasms*
  • Polyurethanes
  • Sleep Apnea Syndromes* / complications
  • Sleep Apnea Syndromes* / therapy

Substances

  • Polyurethanes
  • polyurethane foam